Canada markets closed

Cerevel Therapeutics Holdings, Inc. (CERE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
34.96-0.36 (-1.02%)
At close: 04:00PM EST
34.96 0.00 (0.00%)
After hours: 04:05PM EST
Full screen
Loading interactive chart...
  • GlobeNewswire

    Cerevel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates on Wednesday, February 22, 2023

    CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report fourth quarter and full year 2022 financial results and business updates on Wednesday, February 22, 2023, before the U.S. financial markets open. Management will host a conference call to discuss fourth quarter and full year 2022 financial results and business updates on Wednesday, Febr

  • GlobeNewswire

    Cerevel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference and Provide Pipeline Update

    Initiated Phase 1 healthy volunteer trial to support development of emraclidine in Alzheimer’s disease psychosis in Q4 2022; second potential indication as a once-daily treatment Phase 2 proof-of-concept darigabat panic disorder trial to be initiated in Q2 2023 Multiple data readouts and cash runway into 2025 to support advancement of diverse pipeline of novel neuroscience drug candidates Cerevel presentation to take place on January 10 at 8:15 a.m. PT/11:15 a.m. ET CAMBRIDGE, Mass., Jan. 09, 20

  • GlobeNewswire

    Cerevel Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and chief executive officer Tony Coles, M.D., will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference. Dr. Coles will be joined by additional members of the executive team for the question-and-answer portion of the presentation. Date: Tuesday, January 10, 2023 Form